This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Narvekar, N. Articles by Baird, D. T. Search for Related Content PubMed PubMed Citation Articles by Narvekar, N. Articles by Baird, D. T.

Low-Dose Mifepristone Inhibits Endometrial Proliferation and Up-Regulates Androgen Receptor

Contraceptive Development Network, Center for Reproductive Biology (N.N., S.C., H.O.D.C., D.T.B.), Edinburgh, United Kingdom EH16 4SB; and Shanghai Institute of Family Planning Technical Instruction, International Peace Maternity and Child Health Hospital, China Welfare Institute (S.L., L.C.), Shanghai 200030, People’s Republic of China

Address all correspondence and requests for reprints to: Prof. David T. Baird, Contraceptive Development Network, Chancellor’s Building, 49 Little France Crescent, Edinburgh, United Kingdom EH16 4SB. E-mail: dtbaird{at}ed.ac.uk.

Mifepristone in daily low doses has contraceptive potential by inhibiting ovulation. Follicular development is maintained, and although the endometrium is exposed to unopposed estrogen, there are no signs of hyperplasia or atypia. The mechanism of this antiestrogenic action is unknown. We have investigated the effect of daily low-dose mifepristone on proliferation markers and steroid receptors in surface epithelium, glands, and stroma of the endometrium. Endometrial biopsies were collected from 16 women before (late proliferative) and 60 and 120 d after taking 2 or 5 mg mifepristone daily for 120 d. Endometrial proliferation (H3 mitosis marker) and steroid (estrogen, progesterone, and androgen) receptor content were studied using standard immunocyotchemistry techniques. There was a significant decrease in the expression of H3 mitosis marker (P 0.001) and progesterone receptor (P < 0.05) in endometrial glands and stroma by d 60 of treatment. In contrast, the expression of androgen receptor increased (P < 0.01) in glands, surface epithelium, and stroma compared with the pretreatment sample. These changes were maintained at 120 d of treatment. The expression of estrogen receptor was unchanged in stroma and surface epithelium; however, there was a significant decrease in expression after 120 d of treatment (P = 0.034). As androgens can antagonize estrogen action, enhanced glandular androgen receptor expression induced by mifepristone could play a role in its antiproliferative effects.

This work was supported by a grant to the Contraceptive Development Network from the Department for International Development and the Medical Research Council, United Kingdom (G9523250). Mifepristone was supplied through the WHO Special Program of Research, Development, and Research Training in Human Reproduction (Project 96503).

Abbreviations: AR, Androgen receptor; BMI, body mass index; DAB, 3,3'-diaminobenzidine; ER, estrogen receptor; NGS, nonimmune goat serum; NHS, nonimmune horse serum; PCOS, polycystic ovarian syndrome; PR, progesterone receptor.

This article has been cited by other articles:

				H. O. D. Critchley and P. T. K. Saunders Hormone Receptor Dynamics in a Receptive Human Endometrium Reproductive Sciences, February 1, 2009; 16(2): 191 - 199. [Abstract] [PDF]

				S. Ravet, C. Munaut, S. Blacher, G. Brichant, S. Labied, A. Beliard, N. Chabbert-Buffet, P. Bouchard, J.-M. Foidart, and A. Pintiaux Persistence of an Intact Endometrial Matrix and Vessels Structure in Women Exposed to VA-2914, a Selective Progesterone Receptor Modulator J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4525 - 4531. [Abstract] [Full Text] [PDF]

				S. Bai, G. Grossman, L. Yuan, B. A. Lessey, F. S. French, S. L. Young, and E. M. Wilson Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation Mol. Hum. Reprod., February 1, 2008; 14(2): 107 - 116. [Abstract] [Full Text] [PDF]

				F. M. Horne and D. L. Blithe Progesterone receptor modulators and the endometrium: changes and consequences Hum. Reprod. Update, November 1, 2007; 13(6): 567 - 580. [Abstract] [Full Text] [PDF]

				J. E. Girling, F. L. Lederman, L. M. Walter, and P. A. W. Rogers Progesterone, But Not Estrogen, Stimulates Vessel Maturation in the Mouse Endometrium Endocrinology, November 1, 2007; 148(11): 5433 - 5441. [Abstract] [Full Text] [PDF]

				O. Heikinheimo, S. Vani, O. Carpen, A. Tapper, P. Harkki, E.-M. Rutanen, and H. Critchley Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study Hum. Reprod., September 1, 2007; 22(9): 2515 - 2522. [Abstract] [Full Text] [PDF]

				H. Zang, L. Sahlin, B. Masironi, E. Eriksson, and A. Linden Hirschberg Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2169 - 2175. [Abstract] [Full Text] [PDF]

				A.R.W. Williams, H.O.D. Critchley, J. Osei, S. Ingamells, I.T. Cameron, C. Han, and K. Chwalisz The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata Hum. Reprod., June 1, 2007; 22(6): 1696 - 1704. [Abstract] [Full Text] [PDF]

				A. A. Goyeneche, R. W. Caron, and C. M. Telleria Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo Clin. Cancer Res., June 1, 2007; 13(11): 3370 - 3379. [Abstract] [Full Text] [PDF]

				N. Narvekar, H. O.D. Critchley, L. Cheng, and D. T. Baird Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor Hum. Reprod., September 1, 2006; 21(9): 2312 - 2318. [Abstract] [Full Text] [PDF]

				J. K. Jain, A. Li, W. Yang, P. Minoo, and J. C. Felix Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate Hum. Reprod., March 1, 2006; 21(3): 798 - 809. [Abstract] [Full Text] [PDF]

				N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I. M. Spitz Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications Hum. Reprod. Update, May 1, 2005; 11(3): 293 - 307. [Abstract] [Full Text] [PDF]